Literature DB >> 20499400

Clinical and pathologic factors that predict lymph node yield from surgical specimens in colorectal cancer: a population-based study.

Joanne F Chou1, David Row, Mithat Gonen, Yi-Hai Liu, Deborah Schrag, Martin R Weiser.   

Abstract

BACKGROUND: The National Quality Forum endorses the recommendation of examining at least 12 lymph nodes (LNs) from colorectal cancer (CRC) specimens. However, heterogeneity in LN harvest exists. The objective of this study was to investigate the clinicopathologic factors that influence LN yield.
METHODS: The authors used the Surveillance, Epidemiology, and End Results database to identify patients who were diagnosed with stage I, II, and III CRC between 1994 and 2005. Poisson regression was used to model the number of LNs examined as a function of individual clinicopathologic factors, including age, sex, race, year of diagnosis, geographic region, anatomic site, preoperative radiation, tumor size, tumor classification, tumor differentiation, and LN positivity.
RESULTS: In total, 153,483 patients with CRC were identified. The mean number of LNs examined (+/- standard deviation) was 12 (+/-9.3). Separate multivariate analyses revealed that age, year of diagnosis, tumor size, and tumor classification were significant predictors of LN yield for colon and extraperitoneal rectal cancers (P < .01 for all covariates). Tumor location and radiotherapy were significant predictors of LN yield in patients with colon cancer and rectal cancer, respectively. Overall LN yields increased between 2% and 3% annually.
CONCLUSIONS: Despite the increasing yields observed over time, patients with rectal cancer and older patients who had distally located, early colon cancer were less likely to meet the benchmark yield of 12 LNs. Further investigation into how LN yield is influenced by alterable factors, such as the extent of mesenteric resection and the pathologic technique, as well as nonalterable factors, such as patient age and tumor location, may reveal innovative ways to improve current staging methods. (c) 2010 American Cancer Society.

Entities:  

Mesh:

Year:  2010        PMID: 20499400      PMCID: PMC4067456          DOI: 10.1002/cncr.25032

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  29 in total

1.  The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined.

Authors:  Richard S Swanson; Carolyn C Compton; Andrew K Stewart; Kirby I Bland
Journal:  Ann Surg Oncol       Date:  2003 Jan-Feb       Impact factor: 5.344

2.  Is there a minimum number of lymph nodes that should be histologically assessed for a reliable nodal staging of T3N0M0 colorectal carcinomas?

Authors:  Gábor Cserni; Vincent Vinh-Hung; Tomasz Burzykowski
Journal:  J Surg Oncol       Date:  2002-10       Impact factor: 3.454

Review 3.  NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer.

Authors: 
Journal:  JAMA       Date:  1990-09-19       Impact factor: 56.272

4.  A new approach to rectal cancer.

Authors:  R J Heald
Journal:  Br J Hosp Med       Date:  1979-09

5.  Lymph node recovery from colorectal tumor specimens: recommendation for a minimum number of lymph nodes to be examined.

Authors:  Fabio Cianchi; Annarita Palomba; Vieri Boddi; Luca Messerini; Filippo Pucciani; Giuliano Perigli; Paolo Bechi; Camillo Cortesini
Journal:  World J Surg       Date:  2002-01-15       Impact factor: 3.352

6.  Prognostic evaluation of stage B colon cancer patients is improved by an adequate lymphadenectomy: results of a secondary analysis of a large scale adjuvant trial.

Authors:  Mario Prandi; Rita Lionetto; Antonio Bini; Gianfranco Francioni; Giuseppe Accarpio; Antonio Anfossi; Ezio Ballario; Giuseppe Becchi; Stefano Bonilauri; Andrea Carobbi; Paolo Cavaliere; Domenico Garcea; Lucio Giuliani; Eugenio Morziani; Franco Mosca; Antonio Mussa; Massimo Pasqualini; Domenico Poddie; Federico Tonetti; Luciano Zardo; Riccardo Rosso
Journal:  Ann Surg       Date:  2002-04       Impact factor: 12.969

7.  Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089.

Authors:  T E Le Voyer; E R Sigurdson; A L Hanlon; R J Mayer; J S Macdonald; P J Catalano; D G Haller
Journal:  J Clin Oncol       Date:  2003-08-01       Impact factor: 44.544

Review 8.  Potency, cure, and local control in the operative treatment of rectal cancer.

Authors:  W E Enker
Journal:  Arch Surg       Date:  1992-12

9.  Impact of the number of negative nodes on disease-free survival in colorectal cancer patients.

Authors:  Jan H Wong; B Jason Bowles; Racquel Bueno; David Shimizu
Journal:  Dis Colon Rectum       Date:  2002-10       Impact factor: 4.585

10.  Lymph node retrieval and assessment in stage II colorectal cancer: a population-based study.

Authors:  F C Wright; C H L Law; L Last; M Khalifa; A Arnaout; Z Naseer; N Klar; S Gallinger; A J Smith
Journal:  Ann Surg Oncol       Date:  2003-10       Impact factor: 5.344

View more
  41 in total

1.  Unfavorable effect of small tumor size on cause-specific survival in stage IIA colon cancer, a SEER-based study.

Authors:  Yuwei Wang; Changhua Zhuo; Debing Shi; Hongtu Zheng; Ye Xu; Weilie Gu; Sanjun Cai; Guoxiang Cai
Journal:  Int J Colorectal Dis       Date:  2014-11-13       Impact factor: 2.571

2.  Adjuvant treatment of early colon cancer with micrometastases: results of a national survey.

Authors:  Scott S Short; Alexander Stojadinovic; Aviram Nissan; Zev Wainberg; Deepti Dhall; Kathy Yao; Anton Bilchik
Journal:  J Surg Oncol       Date:  2012-02-03       Impact factor: 3.454

3.  Lymph node yield after colectomy for cancer: is absence of mismatch repair a factor?

Authors:  Tushar Samdani; Molly Schultheis; Zsofia Stadler; Jinru Shia; Tiffany Fancher; Justine Misholy; Martin R Weiser; Garrett M Nash
Journal:  Dis Colon Rectum       Date:  2015-03       Impact factor: 4.585

4.  The positive impact of surgical quality control on adequate lymph node harvest by standardized laparoscopic surgery and national quality assessment program in colorectal cancer.

Authors:  Daeyoun David Won; Sung Bong Choi; Yoon Suk Lee; Seong Taek Oh; Jun Gi Kim; In Kyu Lee
Journal:  Int J Colorectal Dis       Date:  2017-02-11       Impact factor: 2.571

5.  Less than 12 lymph nodes in the surgical specimen after neoadjuvant chemo-radiotherapy: an indicator of tumor regression in locally advanced rectal cancer?

Authors:  Jaiprakash Gurawalia; Kapil Dev; Sandeep P Nayak; Vishnu Kurpad; Arun Pandey
Journal:  J Gastrointest Oncol       Date:  2016-12

6.  Mesenteric root dissection with individualized ileo-colic vessel ligation versus mesenteric pedicle stapling.

Authors:  Ilan Kent; Yaron Rudnicki; Yasmin Abu-Ghanem; Ian White; Baruch Spitz; Shmuel Avital
Journal:  Surg Endosc       Date:  2015-10-20       Impact factor: 4.584

Review 7.  Colorectal cancer and lymph nodes: the obsession with the number 12.

Authors:  Giovanni Li Destri; Isidoro Di Carlo; Roberto Scilletta; Beniamino Scilletta; Stefano Puleo
Journal:  World J Gastroenterol       Date:  2014-02-28       Impact factor: 5.742

8.  CD169 identifies an activated CD8(+) T cell subset in regional lymph nodes that predicts favorable prognosis in colorectal cancer patients.

Authors:  Jiali Zhang; Jing Xu; Rong-Xin Zhang; Yi Zhang; Qing-Jian Ou; Jin-Qing Li; Ze-Zhou Jiang; Xiao-Jun Wu; Yu-Jing Fang; Limin Zheng
Journal:  Oncoimmunology       Date:  2016-04-29       Impact factor: 8.110

Review 9.  Non-surgical factors influencing lymph node yield in colon cancer.

Authors:  Patrick Wood; Colin Peirce; Jurgen Mulsow
Journal:  World J Gastrointest Oncol       Date:  2016-05-15

10.  Stage II colon cancer staging using the number of retrieved lymph nodes may be superior to current TNM staging for prognosis stratification: the Japanese study group for postoperative follow-up of colorectal cancer.

Authors:  Shimpei Ogawa; Michio Itabashi; Yoshiko Bamba; Kimitaka Tani; Shigeki Yamaguchi; Shinichi Yamauchi; Kenichi Sugihara
Journal:  Int J Colorectal Dis       Date:  2021-07-24       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.